The vaccine Development Pathway

David W C Beasley

doi:10.1002/9781118638033.ch2

The vaccine Development Pathway

David W C Beasley

Research services

Research output: Chapter in Book/Report/Conference proceeding › Chapter

2 Scopus citations

Abstract

The decision to develop a vaccine is based on analysis of need and, in most cases, potential returns on the significant investment of time and resources required to move a candidate product from initial development through to licensure. The vaccine development pathway encompasses a series of highly regulated milestones designed to assess the safety and efficacy of a candidate vaccine via nonclinical testing, using animal models and in vitro assays, and in phased clinical trials in humans. Regulatory oversight also aims to ensure the consistency of its manufacture during the investigational phases and following its approval and licensure.

Original language	English (US)
Title of host publication	Vaccinology
Subtitle of host publication	An Essential Guide
Publisher	Wiley-Blackwell
Pages	33-42
Number of pages	10
ISBN (Electronic)	9781118638033
ISBN (Print)	9780470656167
DOIs	https://doi.org/10.1002/9781118638033.ch2
State	Published - Dec 9 2014

Keywords

Biologics license application
Clinical trials
Investigational new drug
National regulatory authority
Nonclinical testing

ASJC Scopus subject areas

General Medicine

Access to Document

10.1002/9781118638033.ch2

Cite this

@inbook{77cb564a515b49928d1bd2aeb3086674,

title = "The vaccine Development Pathway",

abstract = "The decision to develop a vaccine is based on analysis of need and, in most cases, potential returns on the significant investment of time and resources required to move a candidate product from initial development through to licensure. The vaccine development pathway encompasses a series of highly regulated milestones designed to assess the safety and efficacy of a candidate vaccine via nonclinical testing, using animal models and in vitro assays, and in phased clinical trials in humans. Regulatory oversight also aims to ensure the consistency of its manufacture during the investigational phases and following its approval and licensure.",

keywords = "Biologics license application, Clinical trials, Investigational new drug, National regulatory authority, Nonclinical testing",

author = "Beasley, {David W C}",

note = "Publisher Copyright: {\textcopyright} 2015 John Wiley & Sons, Ltd.",

year = "2014",

month = dec,

day = "9",

doi = "10.1002/9781118638033.ch2",

language = "English (US)",

isbn = "9780470656167",

pages = "33--42",

booktitle = "Vaccinology",

publisher = "Wiley-Blackwell",

}

TY - CHAP

T1 - The vaccine Development Pathway

AU - Beasley, David W C

PY - 2014/12/9

Y1 - 2014/12/9

N2 - The decision to develop a vaccine is based on analysis of need and, in most cases, potential returns on the significant investment of time and resources required to move a candidate product from initial development through to licensure. The vaccine development pathway encompasses a series of highly regulated milestones designed to assess the safety and efficacy of a candidate vaccine via nonclinical testing, using animal models and in vitro assays, and in phased clinical trials in humans. Regulatory oversight also aims to ensure the consistency of its manufacture during the investigational phases and following its approval and licensure.

AB - The decision to develop a vaccine is based on analysis of need and, in most cases, potential returns on the significant investment of time and resources required to move a candidate product from initial development through to licensure. The vaccine development pathway encompasses a series of highly regulated milestones designed to assess the safety and efficacy of a candidate vaccine via nonclinical testing, using animal models and in vitro assays, and in phased clinical trials in humans. Regulatory oversight also aims to ensure the consistency of its manufacture during the investigational phases and following its approval and licensure.

KW - Biologics license application

KW - Clinical trials

KW - Investigational new drug

KW - National regulatory authority

KW - Nonclinical testing

UR - http://www.scopus.com/inward/record.url?scp=84976443371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976443371&partnerID=8YFLogxK

U2 - 10.1002/9781118638033.ch2

DO - 10.1002/9781118638033.ch2

M3 - Chapter

AN - SCOPUS:84976443371

SN - 9780470656167

SP - 33

EP - 42

BT - Vaccinology

PB - Wiley-Blackwell

ER -

The vaccine Development Pathway

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this